ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Joseph, Stancy ^a   Deneke, Victoria E ^b   Cowden Dahl, Karen D ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AT RICH INTERACTIVE DOMAIN 3B PROTEIN; BIM PROTEIN; CASPASE 10; CASPASE 7; DEATH RECEPTOR; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR PEA3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; AT RICH INTERACTIVE DOMAIN 3B GENE; CANCER CELL CULTURE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL NUCLEUS; CELL TYPE; CONTROLLED STUDY; CYTOSOL; EXON; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ALTERNATIVE SPLICING; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864462517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042159     Document Type: Article

References (40)

1. AmericanCancerSociety (2010) Global Cancer Facts and Figures 2011.
2. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG, ((2009)) The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11:: 1208--1215.
3. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. ((2007)) MicroRNA signatures in human ovarian cancer. Cancer Research 67:: 8699--8707.
4. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. ((2008)) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:: 2690--2695.
5. Kortschak RD, Tucker PW, Saint R, ((2000)) ARID proteins come in from the desert. Trends Biochem Sci 25:: 294--299.
6. Wilsker D, Probst L, Wain HM, Maltais L, Tucker PW, et al. ((2005)) Nomenclature of the ARID family of DNA-binding proteins. Genomics 86:: 242--251.
7. Tidwell JA, Schmidt C, Heaton P, Wilson V, Tucker PW, ((2011)) Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription. Mol Immunol 49:: 260--272.
8. Wilsker D, Patsialou A, Dallas PB, Moran E, ((2002)) ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ 13:: 95--106.
9. Numata S, Claudio PP, Dean C, Giordano A, Croce CM, ((1999)) Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product. Cancer Research 59:: 3741--3747.
10. Kim D, Probst L, Das C, Tucker PW, ((2007)) REKLES is an ARID3-restricted multifunctional domain. J Biol Chem 282:: 15768--15777.
11. Webb CF, Smith EA, Medina KL, Buchanan KL, Smithson G, et al. ((1998)) Expression of bright at two distinct stages of B lymphocyte development. J Immunol 160:: 4747--4754.
12. Webb CF, Bryant J, Popowski M, Allred L, Kim D, et al. ((2011)) The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development. Mol Cell Biol 31:: 1041--1053.
13. Casanova JC, Uribe V, Badia-Careaga C, Giovinazzo G, Torres M, et al. ((2011)) Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements. Development 138:: 1195--1205.
14. Kobayashi K, Era T, Takebe A, Jakt LM, Nishikawa S, ((2006)) ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Research 66:: 8331--8336.
15. Takebe A, Era T, Okada M, Martin Jakt L, Kuroda Y, et al. ((2006)) Microarray analysis of PDGFR alpha+ populations in ES cell differentiation culture identifies genes involved in differentiation of mesoderm and mesenchyme including ARID3b that is essential for development of embryonic mesenchymal cells. Dev Biol 293:: 25--37.
16. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, et al. ((1992)) Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 10:: 529--535.
17. Stewart CJ, Owens OJ, Richmond JA, McNicol AM, ((1992)) Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol 11:: 266--272.
18. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, et al. ((2011)) Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 11:: 50--57.
19. Huang SM, Harari PM, ((1999)) Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17:: 259--269.
20. Cowden Dahl KD, Zeineldin R, Hudson LG, ((2007)) PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 5:: 413--421.
21. Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, et al. ((2010)) Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Research 70:: 9185--9196.
22. Hanahan D, Weinberg RA, ((2000)) The hallmarks of cancer. Cell 100:: 57--70.
23. Ellerbroek SM, Hudson LG, Stack MS, ((1998)) Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 78:: 331--337.
24. Faber A, Corcoran RB, Ebi H, Sequist LV, Waltman BA, et al. ((2011)) BIM expression in treatment naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1:: 352--365.
25. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. ((2007)) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315:: 856--859.
26. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, et al. ((2008)) BAX activation is initiated at a novel interaction site. Nature 455:: 1076--1081.
27. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, et al. ((2011)) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6:: e18064.
28. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ, ((2006)) TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer (vol 84, pg 87, 2006). Immunology and Cell Biology 84:: 238--238.
29. Sayers TJ, Murphy WJ, ((2006)) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55:: 76--84.
30. Chen G, Goeddel DV, ((2002)) TNF-R1 signaling: a beautiful pathway. Science 296:: 1634--1635.
31. Hayden MS, Ghosh S, ((2008)) Shared principles in NF-kappaB signaling. Cell 132:: 344--362.
32. Kovalenko A, Wallach D, ((2006)) If the prophet does not come to the mountain: Dynamics of signaling complexes in NF-kappa B activation. Molecular Cell 22:: 433--436.
33. Wajant H, Pfizenmaier K, Scheurich P, ((2003)) Tumor necrosis factor signaling. Cell Death and Differentiation 10:: 45--65.
34. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, et al. ((1999)) Tumor necrosis factor receptor and Fas signaling mechanisms. Annual Review of Immunology 17:: 331--367.
35. Kelley SK, Ashkenazi A, ((2004)) Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:: 333--339.
36. Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM, ((2007)) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102:: 442--452.
37. Bevis KS, Buchsbaum DJ, Straughn JM, ((2010)) Overcoming TRAIL resistance in ovarian carcinoma. Gynecologic Oncology 119:: 157--163.
38. Tomek S, Horak P, Pribill I, Haller G, Rossler M, et al. ((2004)) Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecologic Oncology 94:: 107--114.
39. Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, et al. ((1983)) Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. Am J Obstet Gynecol 146:: 607--612.
40. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, et al. ((1994)) Secretion of Extracellular Matrix-Degrading Proteinases Is Increased in Epithelial Ovarian-Carcinoma. International Journal of Cancer 56:: 552--559.